Cell>Point Announces Agreement with FDA on Special Protocol Assessment for Phase 3 Trial of Technetium-99m-EC-G for Imaging Lung Cancer

Published: Mar 13, 2012

CENTENNIAL, Colo.--(BUSINESS WIRE)--Cell>Point announced today that it has received a letter from the U.S. Food and Drug Administration (FDA) indicating agreement on a Special Protocol Assessment (SPA) for Cell>Point’s Phase 3 pivotal clinical study of technetium-99m-EC-G in lung cancer.

Back to news